Skip to content

Right/Left Discrimination Training on Fibromyalgia Patients

Investigating the Effects of Right/Left Discrimination Training on Pain Perception and Functional Disability in Fibromyalgia Patients: A Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05915598
Enrollment
64
Registered
2023-06-23
Start date
2023-06-25
Completion date
2024-08-04
Last updated
2023-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Brief summary

To determine whether a targeted right/left discrimination training program can improve pain perception and functional disability in fibromyalgia patients.

Interventions

OTHERRight/left discrimination training

Participants will use recognize app by Neuro-orthopedic institute (NOI) for daily right/left discrimination training. The training will include visual and auditory stimuli, with tasks such as identifying the laterality of images and sounds. Participants will engage in training for 20 minutes per day, 5 days per week, over a six-week period. Weekly monitoring and feedback will be provided by the research team

OTHERusual care

Usual care: Participants will continue their usual care management for fibromyalgia, including any prescribed medications and physician consultations. No specific right/left discrimination training will be provided to the control group. Follow-up assessments: Participants in the control group will undergo the same follow-up assessments as the intervention group to evaluate changes in pain perception, functional disability, and cognitive function.

Sponsors

Ahram Canadian University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
35 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of fibromyalgia according to the 2016 American College of Rheumatology criteria * Adults between 35 - 55 years old * Both sexes * Stable medication use for at least one month prior to enrollment

Exclusion criteria

* History of other musculoskeletal or neurological disorders * Current involvement in another pain management program or study

Design outcomes

Primary

MeasureTime frameDescription
Pain intensity by The Numeric Pain Rating Scale (NPRS)Changes in pain intensity at baseline, 6 weeks and 12 weeks.The Numeric Pain Rating Scale (NPRS) will be used to assess pain intensity at baseline, 3 weeks, 6 weeks (post-intervention), and 12 weeks (follow-up). Participants will rate their pain on an 11-point scale, ranging from 0 (no pain) to 10 (worst imaginable pain).
Functional disability by The Fibromyalgia Impact Questionnaire (FIQ)Changes in FIQ at baseline, 6 weeks and 12 weeks.The Fibromyalgia Impact Questionnaire (FIQ) will be used to assess functional disability at baseline, 6 weeks, and 12 weeks. The FIQ is a self-report questionnaire containing 21 items related to physical functioning, work status, depression, anxiety, sleep, pain, stiffness, fatigue, and well-being.
Right/left discrimination ability by Recognize smartphone applicationChanges in Right/left discrimination ability at baseline, 6 weeks and 12 weeks.Recognize app by NOI will be used to assess right/left discrimination ability at baseline, 6 weeks, and 12 weeks. This test will include a series of right/left discrimination tasks similar to those used in the training program.

Secondary

MeasureTime frameDescription
Cognitive function by The Montreal Cognitive Assessment (MoCA)Changes in MoCA at baseline, 6 weeks and 12 weeks.The Montreal Cognitive Assessment (MoCA) will be used to assess cognitive function at baseline, 6 weeks, and 12 weeks. The MoCA is a brief screening tool designed to detect mild cognitive impairment and includes tasks related to memory, language, visuospatial skills, attention, and executive function.

Countries

Egypt

Contacts

Primary ContactMohamed M ElMeligie, Ph.d
mohamed.elmeligie@acu.edu.eg+201064442032

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026